Poxel SA (POXEL) - Total Liabilities
Based on the latest financial reports, Poxel SA (POXEL) has total liabilities worth €66.41 Million EUR (≈ $77.63 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore POXEL net assets growth trend to track the company's year-over-year net asset growth rate.
Poxel SA - Total Liabilities Trend (2010–2024)
This chart illustrates how Poxel SA's total liabilities have evolved over time, based on quarterly financial data. See how much free cash does Poxel SA generate to measure how efficiently the company converts operating cash flow to free cash.
Poxel SA Competitors by Total Liabilities
The table below lists competitors of Poxel SA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
SeaStar Medical Holding Corporation
NASDAQ:ICU
|
USA | $3.74 Million |
|
Gold By Gold
PA:ALGLD
|
France | €3.39 Million |
|
Schroder Asia Pacific Fund
LSE:SDP
|
UK | GBX44.96 Million |
|
Nam Sung
KO:004270
|
Korea | ₩172.93 Billion |
|
Idealist Gayrimenkul Yatirim Ortakligi AS
IS:IDGYO
|
Turkey | TL529.97 Million |
|
Sanko Diecasting (Thailand) Public Company Limited
BK:SANKO
|
Thailand | ฿228.94 Million |
|
Libet S.A.
WAR:LBT
|
Poland | zł22.31 Million |
|
Nextedia
PA:ALNXT
|
France | €22.49 Million |
Liability Composition Analysis (2010–2024)
This chart breaks down Poxel SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Poxel SA stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.26 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.08 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 13.28 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Poxel SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Poxel SA (2010–2024)
The table below shows the annual total liabilities of Poxel SA from 2010 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €73.87 Million ≈ $86.36 Million |
+37.04% |
| 2023-12-31 | €53.90 Million ≈ $63.02 Million |
+1.79% |
| 2022-12-31 | €52.95 Million ≈ $61.91 Million |
+13.44% |
| 2021-12-31 | €46.68 Million ≈ $54.58 Million |
+22.21% |
| 2020-12-31 | €38.20 Million ≈ $44.66 Million |
+15.19% |
| 2019-12-31 | €33.16 Million ≈ $38.77 Million |
-33.33% |
| 2018-12-31 | €49.73 Million ≈ $58.14 Million |
+4.87% |
| 2017-12-31 | €47.43 Million ≈ $55.45 Million |
+334.37% |
| 2016-12-31 | €10.92 Million ≈ $12.76 Million |
+23.79% |
| 2015-12-31 | €8.82 Million ≈ $10.31 Million |
-46.13% |
| 2014-12-31 | €16.37 Million ≈ $19.14 Million |
-49.27% |
| 2013-12-31 | €32.28 Million ≈ $37.73 Million |
+310.22% |
| 2012-12-31 | €7.87 Million ≈ $9.20 Million |
+178.30% |
| 2011-12-31 | €2.83 Million ≈ $3.31 Million |
+33.66% |
| 2010-12-31 | €2.12 Million ≈ $2.47 Million |
-- |
About Poxel SA
Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic pathophysiology, type 2 diabetes, and liver diseases. It also develops treatments for rare metabolic diseases and associated steatohepatitis to metabolic dysfunction. The company's lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the tr… Read more